HIND (Vyome Holdings Inc.) stock: $1.58, $11.1M market cap, $7.9M cash, $4.0M EV, $13.9M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
What they do
Our Company On August 15, 2025, ReShape Lifesciences Inc. (now known as Vyome Holdings, Inc.) (the “Company”) completed the merger pursuant to the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the “Merger Agreement”), by and among the Company, Raider Lifesciences Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and Vyome Therapeutics, Inc.
malodor of malignant fungating wounds (MFW) in advanced cancer(Phase 2)
Catalysts
— first half of 2026
Status note Lead program (post-August 2025 merger with Vyome). Dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator topical gel; same active agent as an FDA-approved eye drop (NDA#22-308) for bacterial conjunctivitis. Phase 1 (2017) and Phase 2 randomized dose-ranging studies completed; VB-1953 QD dose supported for Phase 3; pivotal study design to be informed by Phase 2. Investigator-initiated study ongoing in malodorous MFW. VT-1908 also listed in the biotechnology segment but undescribed in excerpts.
Luliconazole
Approved · ActiveModality: topical
Partnerships Sun Pharma: development and licensing agreement for additional development and commercialization in India (sales commenced)
Indications
anti-fungal (topical)(Approved)
Status note Anti-fungal product commercialized in India via Sun Pharma; also a reformulated topical anti-fungal shampoo based on the MRT platform commercialized in India. No specific indication named in excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.